The purpose of this study is to determine whether application of low dose Delta9-Tetrahydrocannabinol can prevent the development of chronic pain in patients with acute CRPS.
Recent animal data suggest that the endocannabinoid system is a promising target in the prevention of chronic pain. It has been shown that the endocannabinoid system modifies excitatory and inhibitory currents in structures involved in the development of chronic pain such as the amygdala. CRPS is a neuropathic pain condition, which is known to become chronic in a significant percentage. The study compares the effect of low dose Delta9-Tetrahydrocannabinol (90 days) and placebo in acute CRPS. All patients will receive a standard treatment consisting of drug therapy and physiotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
100
Department of Anesthesiology, Interdisciplinary Pain Clinic Grosshadern, Universitiy of Munich
Munich, Germany
RECRUITINGIncidence of chronic pain at one year assessed with Visual Analogue Scale (VAS)
Changes in somatosensory phenotype at one year assessed with Quantitative Sensory Testing (QST)
Motor function of the affected extremity at one year assessed with a biometric evaluation
Changes in Health Related Quality of Life at one year assessed with SF-36
Changes in plasma endocannabinoid levels at 30, 60, 90 days and at one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.